Baseline characteristics | From meta to CR/nCR | Time from CR/nCR to the following conditions (months) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No | Age | Time to meta | Baseline metastasesa | Regimen before CR/nCR | Time to CR/nCR | WLI | Maintenance therapy | Status at last follow-upb | Last follow up | Local recurrence or metastatis | Death |
1 | 8y | 8.9 | L | AVI | 1.7 | Yes | VI | DOD1 | - | 12.4 | 30.0 |
2 | 21y | 10.3 | P | AVI | 3.6 | Yes | CTX + Celecoxib | DOD2 | - | 6.2 | 37.5 |
3 | 21y | 11.7 | L | AVI | 4.0 | Yes | AVI | NED | 38.8 | - | - |
4 | 23y | 15.2 | L | AVI | 6.3 | Yes | VI | AWD | 33.4 | 3.5 | - |
5 | 36y | 41.7 | L | AVI | 7.0 | Yes | AVI | AWD | 32.3 | 17.2 | - |
6 | 12y | 8.5 | L + P | AVI | 5.7 | Yes | A | DOD2 | - | 2.6 | 22.0 |
7 | 18y | 21.7 | L + P | AVI | 5.8 | Yes | VI + olaparib | DOD2 | - | 6.6 | 14.4 |
8 | 8y | 18.7 | L | AVI | 2.8 | Yes | A | AWD | 33.0 | 6.5 | - |
9 | 39y | 29.9 | L | AVI | 4.2 | Yes | AVI | AWD | 28.6 | 15.9 | - |
10 | 8y | 0.0 | L | VDC-IE | 3.1 | No | CTX + Celecoxib | AWD | 63.8 | 31.5 | - |
11y | 14.7 | L | AVI | 7.5 | Yes | A | AWD | 24.8 | 22.8 | - | |
11 | 13y | 0.0 | L | VDC-IE | 6.2 | No | No | DOD1 | - | 7.5 | 26.4 |
15y | 23.5 | L | VIT | 3.5 | No | No | DOD1 | - | 4.1 | 5.6 | |
12 | 4y | 0.0 | L | VDC-IE | 4.1 | No | No | AWD | 57.7 | 12.9 | - |
6y | 17.1 | L | IE-VI | 6.5 | No | CTX + Celecoxib | AWD | 38.3 | 17.8 | - | |
8y | 41.4 | L | VIT | 9.8 | No | No | AWD | 10.7 | 8.7 | - | |
13 | 24y | 0.0 | L | VDC-IE | 5.4 | No | No | DOD1 | - | 9.3 | 16.8 |
14 | 28y | 15.3 | L | AVI | 4.6 | Yes | VIT | DOD1 | - | 2.4 | 17.2 |
15 | 30y | 19.7 | L | AVI | 6.4 | Yes | AVI | NED | 33.2 | - | - |
16 | 8y | 18.9 | L | AVI | 4.1 | Yes | VI | DOD2 | - | 2.0 | 12.8 |
17 | 5y | 0.0 | P | VDC-IE | 6.2 | Yes | CTX + Celecoxib | NED | 35.4 | - | - |